These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33371010)

  • 1. LDCT lung cancer screening in populations at different risk for lung cancer.
    Teles GBDS; Macedo ACS; Chate RC; Valente VAT; Funari MBG; Szarf G
    BMJ Open Respir Res; 2020 Feb; 7(1):. PubMed ID: 33371010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of lung cancer risk model (PLCO
    Lebrett MB; Balata H; Evison M; Colligan D; Duerden R; Elton P; Greaves M; Howells J; Irion K; Karunaratne D; Lyons J; Mellor S; Myerscough A; Newton T; Sharman A; Smith E; Taylor B; Taylor S; Walsham A; Whittaker J; Barber PV; Tonge J; Robbins HA; Booton R; Crosbie PAJ
    Thorax; 2020 Aug; 75(8):661-668. PubMed ID: 32631933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial.
    Tammemägi MC; Ten Haaf K; Toumazis I; Kong CY; Han SS; Jeon J; Commins J; Riley T; Meza R
    JAMA Netw Open; 2019 Mar; 2(3):e190204. PubMed ID: 30821827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment.
    Pinsky PF; Gierada DS; Black W; Munden R; Nath H; Aberle D; Kazerooni E
    Ann Intern Med; 2015 Apr; 162(7):485-91. PubMed ID: 25664444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
    Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
    EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.
    Tammemägi MC; Ruparel M; Tremblay A; Myers R; Mayo J; Yee J; Atkar-Khattra S; Yuan R; Cressman S; English J; Bedard E; MacEachern P; Burrowes P; Quaife SL; Marshall H; Yang I; Bowman R; Passmore L; McWilliams A; Brims F; Lim KP; Mo L; Melsom S; Saffar B; Teh M; Sheehan R; Kuok Y; Manser R; Irving L; Steinfort D; McCusker M; Pascoe D; Fogarty P; Stone E; Lam DCL; Ng MY; Vardhanabhuti V; Berg CD; Hung RJ; Janes SM; Fong K; Lam S
    Lancet Oncol; 2022 Jan; 23(1):138-148. PubMed ID: 34902336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung cancer screening by nodule volume in Lung-RADS v1.1: negative baseline CT yields potential for increased screening interval.
    Silva M; Milanese G; Sestini S; Sabia F; Jacobs C; van Ginneken B; Prokop M; Schaefer-Prokop CM; Marchianò A; Sverzellati N; Pastorino U
    Eur Radiol; 2021 Apr; 31(4):1956-1968. PubMed ID: 32997182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of Risk Factor-Based Guidelines and Model-Based Chest CT Lung Cancer Screening in World Trade Center-Exposed Fire Department Rescue/Recovery Workers.
    Cleven KL; Vaeth B; Zeig-Owens R; Colbeth HL; Jaber N; Schwartz T; Weiden MD; Markowitz SB; Silvestri GA; Prezant DJ
    Chest; 2021 May; 159(5):2060-2071. PubMed ID: 33279511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Jonas DE; Reuland DS; Reddy SM; Nagle M; Clark SD; Weber RP; Enyioha C; Malo TL; Brenner AT; Armstrong C; Coker-Schwimmer M; Middleton JC; Voisin C; Harris RP
    JAMA; 2021 Mar; 325(10):971-987. PubMed ID: 33687468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Tammemägi MC; Cina K; Kitts AKB; Koop D; Petereit MA; Sargent M; Petereit DG
    Cancer; 2023 Dec; 129(24):3894-3904. PubMed ID: 37807694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple model for predicting lung cancer occurrence in a lung cancer screening program: The Pittsburgh Predictor.
    Wilson DO; Weissfeld J
    Lung Cancer; 2015 Jul; 89(1):31-7. PubMed ID: 25863905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
    Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
    Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol and Rationale for the International Lung Screening Trial.
    Lim KP; Marshall H; Tammemägi M; Brims F; McWilliams A; Stone E; Manser R; Canfell K; Weber M; Connelly L; Bowman RV; Yang IA; Fogarty P; Mayo J; Yee J; Myers R; Atkar-Khattra S; Lam DCL; Rosell A; Berg CD; Fong KM; Lam S;
    Ann Am Thorac Soc; 2020 Apr; 17(4):503-512. PubMed ID: 32011914
    [No Abstract]   [Full Text] [Related]  

  • 14. Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience.
    Tammemägi MC; Darling GE; Schmidt H; Llovet D; Buchanan DN; Leung Y; Miller B; Rabeneck L
    Lung Cancer; 2021 Jun; 156():31-40. PubMed ID: 33887677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography.
    Vogel-Claussen J; Lasch F; Bollmann BA; May K; Kuhlmann A; Schmid-Bindert G; Kaaks R; Barkhausen J; Bohnet S; Reck M
    Rofo; 2022 Dec; 194(12):1333-1345. PubMed ID: 35917826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world Clinical Implementation of Lung Cancer Screening-Evaluating Processes to Improve Screening Guidelines-Concordance.
    Carroll NM; Burnett-Hartman AN; Joyce CA; Kinnard W; Harker EJ; Hall V; Steiner JS; Blum-Barnett E; Ritzwoller DP
    J Gen Intern Med; 2020 Apr; 35(4):1143-1152. PubMed ID: 31974902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the accuracy of the PLCO
    Jantzen R; Ezer N; Camilleri-Broët S; Tammemägi MC; Broët P
    CMAJ Open; 2023; 11(2):E314-E322. PubMed ID: 37041013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing Different Approaches to Leveraging Historical Smoking Exposure Data to Better Select Lung Cancer Screening Candidates: A Retrospective Validation Study.
    Kats DJ; Adie Y; Tlimat A; Greco PJ; Kaelber DC; Tarabichi Y
    Nicotine Tob Res; 2021 Aug; 23(8):1334-1340. PubMed ID: 32974635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.
    Wade S; Weber M; Caruana M; Kang YJ; Marshall H; Manser R; Vinod S; Rankin N; Fong K; Canfell K
    J Thorac Oncol; 2018 Aug; 13(8):1094-1105. PubMed ID: 29689434
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.